Solara Active Pharma Sciences Ltd reported a Q3 FY25 revenue of INR 3,018 million, a 21% year-over-year increase, with EBITDA margins improving to 19.6%. The company plans to carve-out its CRAMS and Polymer business along with the Vizag facility into an independent entity.